Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires $405,793.15 in Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe acquired 26,963 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was purchased at an average price of $15.05 per share, for a total transaction of $405,793.15. Following the transaction, the chief executive officer now directly owns 692,511 shares of the company’s stock, valued at approximately $10,422,290.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Lappe also recently made the following trade(s):

• On Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx stock. The shares were purchased at an average price of $17.13 per share, with a total value of $223,323.81.
• On Monday, September 9th, Mark Lappe purchased 9,500 shares of Inhibrx stock. The shares were acquired at an average price of $15.21 per share, for a total transaction of $144,495.00.
• On Friday, September 6th, Mark Lappe acquired 26,000 shares of Inhibrx stock. The stock was acquired at an average price of $15.29 per share, with a total value of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe bought 20,000 shares of Inhibrx stock. The shares were acquired at an average cost of $15.81 per share, for a total transaction of $316,200.00.
• On Thursday, August 29th, Mark Lappe purchased 10,000 shares of Inhibrx stock. The stock was acquired at an average cost of $14.03 per share, with a total value of $140,300.00.

Inhibrx Stock Performance

Shares of INBX opened at $16.99 on Thursday. The company has a 50-day simple moving average of $13.87 and a two-hundred day simple moving average of $23.42. Inhibrx, Inc. has a one year low of $10.80 and a one year high of $18.95.

Inhibrx (NASDAQ:INBX) last released its earnings results on Tuesday, August 13th. The company reported $125.48 EPS for the quarter, beating analysts’ consensus estimates of ($3.60) by $129.08. The firm had revenue of $0.10 million during the quarter. As a group, equities research analysts predict that Inhibrx, Inc. will post 87.5 EPS for the current year.

Wall Street Analyst Weigh In

Separately, JMP Securities assumed coverage on shares of Inhibrx in a research report on Tuesday, July 23rd. They set a “market perform” rating on the stock.

Institutional Trading of Inhibrx

A number of hedge funds have recently modified their holdings of the business. Vestal Point Capital LP bought a new position in shares of Inhibrx in the 4th quarter worth about $58,140,000. PFM Health Sciences LP increased its stake in shares of Inhibrx by 86.4% during the fourth quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock valued at $20,443,000 after purchasing an additional 249,347 shares in the last quarter. MMCAP International Inc. SPC purchased a new position in shares of Inhibrx during the first quarter valued at approximately $15,782,000. Charles Schwab Investment Management Inc. boosted its position in shares of Inhibrx by 8.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock worth $8,735,000 after purchasing an additional 17,762 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of Inhibrx by 8.5% in the 1st quarter. Swiss National Bank now owns 42,000 shares of the company’s stock worth $1,468,000 after buying an additional 3,300 shares during the last quarter. Institutional investors own 82.46% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.